Companies: Cambridge Cognition Holdings Plc
Companies: Cambridge Cognition Holdings Plc (COG:LON)Evgen Pharma Plc (EVG:LON)
Companies: COG IOG MMX TRCS CGH
Companies: Cambridge Cognition Holdings Plc (COG:LON)Silence Therapeutics plc (SLN:LON)
Companies: COG KBT AGL ACC BBB
Companies: Cambridge Cognition Holdings Plc (COG:LON)Oxford BioMedica plc (OXB:LON)
Cambridge Cognition reported FY 2020 results that were in line with its trading update on 19 January; revenues of £6.7m (+34%) and an adjusted pre-tax loss of £0.6m (vs. -£3.0m in 2019), having traded profitably in Q4. Net cash at year-end was £3.0m. Whilst we leave forecasts unchanged, we increase our target price to 125p, which implies a 2021E EV/Sales multiple of 4.3x and signals our confidence in the company meeting these forecasts: this is in line with other health tech companies and reflec
Companies: BOTB COG CHAR MPE PHD QTX IQG BBB
Cambridge Cognition held a very impressive Capital Markets Day yesterday that showcased the digital technology solutions that have established it as a leader in virtual clinical trials. The group targets the large, fast-growing markets for electronic Clinical Outcomes Assessment and central nervous system disorder digital apps. The focus of the CMD was to detail how digital technologies are increasingly being blended into clinical trials, with CV19 accelerating this trend. Over the next decade,
Companies: Cambridge Cognition Holdings Plc (COG:LON)ValiRx PLC (VAL:LON)
Cambridge Cognition ("COG") has provided a trading update for the year ended 31 December 2020 that is ahead of our expectations. Group Revenues grew +34% to £6.7m (2019: £5.0m) and were +7% ahead of DCe of £6.3m. COG delivered significant revenue growth from digital solutions for clinical trials as it increased its focus on commercialisation. The strong beat in Revenue is due to an improved commercial execution across a wider portfolio of products as the Group has placed a key emphasis on crosss
Cambridge Cognition provided a positive FY 2020 trading update, with revenues (+34%), net losses and cash all ahead of expectations, and delivering an EBITDA-positive Q4. After a year of record order intake (£12.7m) and with a year-end order book of £11.2m (+96% on the prior year), the company is positioned to deliver another year of strong growth. This update provides further evidence of (i) the commercial focus that the CEO has instigated, (ii) the cross-selling opportunities for its newer dig
Companies: ALU AMO COG ELCO IOF TCM EVG
It has been a year the likes of which we have never seen before, and hope never to see again. The description of the impact of the CV19 pandemic as K-shaped certainly feels accurate, with some sectors being well placed to benefit from the creative disruption that has engulfed the world, accelerating structural changes, while others through no fault of their own have been severely impacted. This has been the case for the Dowgate portfolio of corporate clients, with our quoted clients falling into
Companies: COG FRAN GRC OTAQ TPX SFOR SEEN WATR
Research Tree provides access to ongoing research coverage, media content and regulatory news on Cambridge Cognition Holdings Plc. We currently have 144 research reports from 6 professional analysts.
OptiBiotix has reported its final results for the year to December 2020, which are largely in-line with the financials reported with the recent ‘Strategy and commercial update'. 2020 was a strong year for the company as its two operational divisions achieved EBITDA profitability supported by increased commercialisation of the group's product range. This commercial moment has continued into 2021, as the company looks to scale its first-generation product sales with new product lines and new terri
Companies: OptiBiotix Health PLC
As midsummer’s day looms (where has this year gone?), there is greater optimism, in general, than may have been anticipated a few months ago. A post-pandemic, ‘vaccine-driven’ recovery demonstrated by increased consumer spending as lockdown measures are lifted has been one of the catalysts. The FTSE 100 has been range-bound in the last month 6,900-7,100. We have seen a combination of broadly positive company results across a range of sectors, further examples of M&A activity and a sequence of ne
Companies: AMYT ARBB ARW BAG BEG BONH BWNG CWK DNK EML EPWN FBD FA/ GPH GSF GNC HUW IGC INSE KAPE KP2 MMAG NRR NESF OTMP ROL RUA SEN SUR TON TOU TXP TGL VLS WINK
CareTech is a specialist social care and educational services provider. This morning, the group has announced interim results to 31 March 2021, which illustrate another positive six month period, particularly when considering the present wider backdrop. An increase in underlying PBT of 31.6% against the prior year benefited from organic growth, as well as the acquisition of Smartbox, transfer in of The Huntercombe Group facilities and a full period contribution from the Middle East. As reported
Companies: CareTech Holdings PLC
Trading has strengthened significantly since restrictions eased in April, especially in the UK. UK brand sales are now up 64% YTD (+18% vs 2019). Further distribution gains are being made, including in the USA and online sales have tripled, albeit off a small base. Net cash has increased to £6.6m (Dec’20, £4.9m). Risk appears to lie to the upside vs prudent forecasts. The re-rating looks well supported to us, and we look forward to the H1 update in July
Companies: Warpaint London PLC
Warpaint has issued a highly positive AGM trading update (covering the financial YTD). Trading is said to have been “encouraging”, with UK brand sales some 18% ahead of pre-covid levels, with good progress in international markets and online sales reported at 3x a year ago. We leave forecasts unchanged at this stage of the year, with 2021F at EPS of 5.3p, although we see growing scope for upgrades if the current momentum can be sustained into H2 2021, and if significant additional Covid disrupti
Evgen reported full-year results to 31 March that were c.£0.3m better than expected, with an adjusted net loss of £2.8m resulting in year-end cash of £11.6m (FC est. £11.3m), which provides a cash runway to at least mid-2023. The company continues to progress SFX-01 in glioma (brain cancer) and metastatic breast cancer (mBC) pre-clinical models, with the aim of commencing a Phase Ib/II trial in Q2 2022 (glioma) and potentially a Phase IIb trial in mBC patients who have become resistant to first-
Companies: Evgen Pharma Plc
There has been a safety halt to the lead human retinal progenitor cell (hRPC) project. The issue was an eye infection in one patient following a successful surgical implantation of the hRPC. The cause is under investigation. If, as we assume, the trial restarts in the next few months, data should be available by Q421, a delay of perhaps three months. This is not significant within the overall developmental pathway and good data are needed to secure any future partnership from mid-2022. The valua
Companies: ReNeuron Group plc
The UK market showed a continued recovery in the first quarter albeit the indices are still well short of their all-time peaks, unlike many of their international peers. The FTSE 100 has risen by 1,186 points (21.4%) since the end of October and the FTSE 250 by 4,304 points (25.0%). The comparable performance since the start of the year is less spectacular- the FTSE 100 has risen by 253 points (3.9%) and the FTSE 250 has risen by 1,070 points (5.0%). The factors behind the sustained rally are fa
Companies: AMYT ARBB CEG BAG BVC BEG BONH BLVN BRSD CML CWK CRPR EYE ECHO FDM FAR FA/ GPH GSF HUW INSE JDG KAPE KP2 MACF MPAC MNZS NESF NBI OTMP OBD PREM QFI RUA SCS SEN SOS SUR TON TOU TXP TGL TCN UEM VLS WYN
AVO’s goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly derisked the project. Now, AVO is working on the verification and validation phase, prior to LIGHT being used on the first patients to support CE marking. In its recent technical update, the company highlighted progress made over the past three months towards a ful
Companies: AVO ARBB ARIX BBGI CLIG DNL FLTA ICGT OCI PCA PIN RECI STX SPO SCE TRX VTA
Further to yesterday's announcement, NetScientific, the international life sciences and sustainability technology investment and commercialisation group, has announced that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), is to issue c.5.3m new shares of common stock to raise gross proceeds of c.$45m. NetScientific currently owns 1,278,000 shares of PDS' common stock, representing 5.7% of its fully diluted share capital prior to the issue.
Companies: NetScientific plc
Strong H2 trading means full year EBITDA is expected to be ‘not less than £6m’, leading us to upgrade our adj PBT/EPS forecasts by 5%. Within this we note lower sales to China (CN), offset by stronger than expected performance in higher margin core markets, including the UK. We have reduced the CN sales mix in unchanged FY21/22 forecasts, with positive implications for earnings quality. Management hopes to resume exports in H1 and, should this be the case, forecast risk would be to the upside. E
Companies: Venture Life Group Plc
Venture Life Group has announced the acquisition of BBI Healthcare, a leading Women's Health and Energy Management/Diabetes company. Venture Life will pay up to £36.0m for the business, which generated revenues of £10.2m and adjusted EBITDA of £2.6m in FY20A. We believe the acquisition will fit well within Venture Life, significantly expanding the group's own brand revenues and providing a number of revenue growth and operational leverage opportunities. The acquisition has been financed by exist
NetScientific, the life sciences and sustainability technology investment and commercialisation group, announced intraday on Thursday 10 June 2021 that it had raised gross proceeds of approximately £7.7m in an oversubscribed fundraising at a price of 130p, a 10.3% discount to the previous day close of 145p. A total of 5,958,123 placing shares will be admitted to trading on 29 June 2021, subject to placing agreements and shareholder approvals. The placing significantly strengthens the balance sh
Continuing its exceptionally strong year, Venture Life has announced it expects to ‘comfortably exceed market expectations' for FY20E. This outperformance stems from all areas of the business, supported by an enlarged order book, €168m multi-year Chinese agreement (+€7m in 2020) and demand for its new branded hand sanitising gel. Venture Life has announced an extension to its Alliance Pharma manufacturing agreement. On top of our March upgrade, we are today, significantly increasing our revenue
Venture Life Group has delivered an outstanding year with revenues up c50% and adjusted EBITDA up over 100%. Revenue growth was delivered both organically and via M&A, and across both the Venture Life brands and the Customer brands divisions. Revenue growth was matched by margin expansion, with gross margin up over 300bps and adjusted EBITDA margin above 20% for the first time. The group closed 2020 with a strong balance sheet able to support M&A. We believe Venture Life is entering 2021 in an e
